StockMarketWire.com - Kidney disease diagnostics company Renalytix AI said it had expanded an investigator group for its lead production, which identifies fast-progressing kidney disease in Type 2 diabetes.

The new advisory members included Jonathan Himmelfarb, from the University of Washington, and Joseph Vassalotti, who was chief medical officer of the National Kidney Foundation and an academic at the Icahn School of Medicine at Mount Sinai.

The additions also included George Bakris, an academic from the University of Chicago.


At 8:36am: [LON:RENX] share price was 0p at 246p



Story provided by StockMarketWire.com